Skip to main content

Vasculitis

      The final day of EULAR 2024 was rich in posters, Late-breaking oral presentations and EULAR updates and recommendations.  Below is a synopsis of the half-day's action.JAK inhibitor Treatment of…
      It has been easy over time to presume that all advanced therapies in a disease area will work as well as each other. We have been so used to the idea that all b/tsDMARDs in rheumatoid arthritis are…
      Summary of #EULAR2024 #ClinicalPearls

      JAKi have expanding disease data
      ✅ #GCA w #UPA
      ✅ Awaiting data in #SLE w #UPA
      6 months ago
      Summary of #EULAR2024 #ClinicalPearls JAKi have expanding disease data ✅ #GCA w #UPA ✅ Awaiting data in #SLE w #UPA & #Deucravacitinib ✅Use in #JIA ✅No new safety signals @rheumnow @eular_org
      Once in remission with
      #rituximab in #GPA
      How long to resize
      500 mg q6 mo for
      4 years?
      ?longer
      ?less
      #EULAR2024 @eular
      6 months ago
      Once in remission with #rituximab in #GPA How long to resize 500 mg q6 mo for 4 years? ?longer ?less #EULAR2024 @eular_org @RheumNow https://t.co/G4kU3v81je
      #EULARBEST
      RCT of #upadacitinib in #GCA

      It works to steroid spare
      15 mg > 7.5 mg in outcomes
      Both >>placebo
      6 months ago
      #EULARBEST RCT of #upadacitinib in #GCA It works to steroid spare 15 mg > 7.5 mg in outcomes Both >>placebo Ethically PBO had slower #prednisone taper Similar to #TCZ data What to choose in GCA IL6i IL17i JAKi @eular_org @RheumNow LBA0001 https://t.co/gy0TEiHxjo
      PMR patients get too much steroid.

      Data across 27 million people in England, n=39,438 with PMR.
      The blue are getting mo
      6 months ago
      PMR patients get too much steroid. Data across 27 million people in England, n=39,438 with PMR. The blue are getting more pred than guidelines. Like everything in rheum: we need to be giving less pred, not more. Lumping PMR in with GCA won’t help. #EULAR2024 POS0411 @RheumNow https://t.co/bsi3lrAafm
      #EULAR2024 POS0234 The effect of prophylactic Septrin in ANCA #vasculitis pts treated with RTX/CyC need further characte
      #EULAR2024 POS0234 The effect of prophylactic Septrin in ANCA #vasculitis pts treated with RTX/CyC need further characterisation. Multicentre study in Korea showed protective effect on Serious Infection btw those treated vs not. Effect was seen in the first 3mths only @RheumNow https://t.co/dCzD21589S
      EULAR Abstract Archive

      OP0283 (2024)
      LONG-TERM EFFICACY TOCILIZUMAB AFTER ULTRA-SHORT GC TO TREAT GCA: 3 Yr FOLLOW-UP O
      6 months ago
      EULAR Abstract Archive OP0283 (2024) LONG-TERM EFFICACY TOCILIZUMAB AFTER ULTRA-SHORT GC TO TREAT GCA: 3 Yr FOLLOW-UP OF THE GUSTO TRIAL 3 day GC pulse immediate 12 mths Toci 85% drug free remission at 4 yrs! https://t.co/XWnzuVMlbn @RheumNow #EULAR2024
      #EULAR2024 LBA0001 New Steroid-sparring therapy for #GCA. Phase 3 RCT showed Upadacitinib 15mg met primary endpoint (sus
      #EULAR2024 LBA0001 New Steroid-sparring therapy for #GCA. Phase 3 RCT showed Upadacitinib 15mg met primary endpoint (sustained clin remission frm Wks 12-52 & adherence to 26Wk GC taper) vs PBO [46% vs 29%] & multiple secondary endpoints. No new safety signals @RheumNow https://t.co/edfSZkMuy2
      ×